INBP · XBRL financial data

Integrated Biopharma financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (INBP's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Cost of goods and services sold	54,079	49,694	46,611	46,433	48,791	43,072
Gross profit	9,480	6,552	4,061	3,884	5,562	800
Selling, general and administrative	3,696	3,807	3,941	3,633	3,542	3,505
Operating income (loss)	5,784	2,745	120	251	2,020	(2,705)
Interest expense	256	128	52	52	46	12
Other income (expense)	57	35	40	(1)	3	(12)
Income tax expense (benefit)	(766)	(1,241)	134	156	1,254	279
Net income (loss)	8,013	3,838	(34)	112	808	(2,842)
Earnings per share, basic USD per share	0.27	0.13	0.00	0.00	0.03	(0.09)
Earnings per share, diluted USD per share	0.25	0.12	0.00	0.00	0.03	(0.09)
Weighted average shares, basic thousands of shares	29,699	29,843	29,950	30,066	30,296	31,060
Weighted average shares, diluted thousands of shares	32,114	32,321	29,950	30,874	31,168	31,060

Fiscal years (INBP's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Cash and cash equivalents	210	331	1,316	1,677	3,615	4,471
Accounts receivable	5,776	4,888	4,511	4,668	5,430	3,334
Inventory	11,695	11,055	10,261	11,244	9,362	9,142
Total current assets	17,998	16,626	16,372	17,875	18,763	17,379
Property and equipment, net	1,742	1,910	1,653	1,885	1,723	1,754
Right-of-use asset	2,365	1,867	2,623	1,790	855	2,929
Total assets	25,440	25,250	25,431	26,207	24,901	25,338
Accounts payable	3,496	3,209	2,266	2,510	2,267	3,200
Current portion of long-term debt	1,457	32	42	—	—	—
Total current liabilities	9,236	5,263	4,828	6,123	4,248	5,802
Long-term debt	0	53	7	—	—	—
Lease liability, non-current	1,870	1,359	1,735	846	221	1,802
Total liabilities	11,106	6,675	6,570	6,969	4,584	7,671
Accumulated deficit	(36,143)	(32,305)	(32,339)	(32,227)	(31,419)	(34,261)
Total stockholders' equity	14,334	18,575	18,861	19,238	20,317	17,667
Total liabilities and equity	25,440	25,250	25,431	26,207	24,901	25,338
Common shares outstanding (cover page) thousands of shares	29,820	29,950	29,950	30,100	31,060	31,060

Fiscal years (INBP's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Net income (loss)	8,013	3,838	(34)	112	808	(2,842)
Stock-based compensation	231	369	320	252	185	192
Depreciation and amortization	337	336	351	319	318	293
Net cash from operating activities	3,050	4,091	1,232	943	2,065	1,241
Purchases of property and equipment	295	486	116	553	191	346
Net cash from investing activities	(199)	(465)	(111)	(553)	(205)	(340)
Net cash from financing activities	(3,043)	(3,505)	(136)	(29)	78	(45)
Net change in cash	(192)	121	985	361	1,938	856

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Integrated Biopharma	4,471	not reported	(1,194)*	31.1M	3.7 quarters	Q4 FY26 10-KJun 30, 2026
PTC Therapeutics	508,894	357,807	(25,311)*	83.5M	—	Q3 FY26 10-QSep 30, 2026
Inhibitor Therapeutics	516	not reported	(775)*	173.8M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Enveric Biosciences	8,296	not reported	(2,445)*	4.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Polomar Health Services	179	1,529	121*	28.4M	—	Q2 FY26 10-QJun 30, 2026
Q/C Technologies	308	not reported	(1,819)*	8.2M	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Oragenics	3,864	not reported	(2,187)*	4.5M	1.8 quarters	Q2 FY26 10-QJun 30, 2026
Jaguar Health	3,788	1,225	(5,338)*	not reported	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Theriva Biologics	11,337	0*	(3,085)*	45.9M	3.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.